ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 393-399

  Muallem, Mustafa Zelal ^a   Braicu, Ioana ^a   Nassir, Mani ^a   Richter, Rolf ^a   Sehouli, Jalid ^a   Arsenic, Ruza ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Epithelial ovarian cancer; ERCC1 expression; Immunohistochemistry staining; Platinum based chemotherapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL; ANTINEOPLASTIC AGENT; CISPLATIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; OVARY PAPILLARY CARCINOMA; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ADOLESCENT; ARTICLE; CYSTADENOCARCINOMA; DRUG RESISTANCE; ENZYME IMMUNOASSAY; ERCC1 EXPRESSION; IMMUNOHISTOCHEMISTRY STAINING; METABOLISM; MIDDLE AGED; MORTALITY; OVARY TUMOR; PLATINUM BASED CHEMOTHERAPY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

EPITHELIAL OVARIAN CANCER; ERCC1 EXPRESSION; IMMUNOHISTOCHEMISTRY STAINING; PLATINUM BASED CHEMOTHERAPY;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, PAPILLARY; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84897026223     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Bae J, Lim MC, Choi J-H, Song Y-J, Lee KS, Kang S, Seo S-S and Park S-Y: Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer. Gynecol Oncol 20: 101-106, 2009.
2. Altaha R, Liang X, Yu JJ and Reed E: Excision repair cross complementing-group 1: Gene expression and platinum resistance parameters in human breast cancer. Int J Mol Med 14: 959-970, 2004.
3. Volker M, Moné MJ, Karmakar P, van Hoffen A, Schul W, Vermeulen W, Hoeijmakers JH, van Driel R, van Zeeland AA and Mullenders LH: Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 8: 213-224, 2001.
4. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB, Hoeijmakers JH and Kanaar R: The structure-specific endonuclease ERCC1-XPF is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787, 2004.
5. Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: The role of DNA repair pathways. Clin Cancer Res 14: 1291-1295, 2008.
6. Reed E: Platinum DNA adduct, nucleotide excision repair and platinum-based anticancer chemotherapy. Cancer Treat Rev 24: 331-344, 1998.
7. Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M and Krivak TC: Pre-treatment tumor expression of ERCC1 in women with advanced-stage epithelial ovarian cancer is not predictive of clinical outcomes: A Gynecologic Oncology Group study. Gynecol Oncol 125: 421-426, 2012.
8. Steffensen KD, Waldstrøm M and Jakobsen A: DNA-repair ERCC1 gene polymorphisms in epithelial ovarian cancer and relation to platinum resistance and survival. Cancer Ther 2: 140-147, 2011.
9. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R and Liu B: ERCC1 mRNA levels and survival of advanced gastric patients treated with a modified FOLFOX regimen. Brit J Cancer 98: 1398-1402, 2008.
10. Kim MK, Cho KJ, Kwon GY, Park SI, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD and Kim SB: ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer 44: 54-60, 2008.
11. Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sánchez JM, Gumerlock PH, Tarón M, Sánchez JJ, Danenberg KD, Danenberg PV and Rosell R: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291, 2002.
12. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD and Kim SB: Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 14: 4225-4231, 2008.
13. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R and Baselga J: Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18: 522-528, 2007.
14. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D and Rosell R. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small cell lung cancer. J Clin Oncol 25: 2747-2754, 2007.
15. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001.
16. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B and Leichman L: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
17. Steffensen KD, Waldstrøm M and Jakobsen A: The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. Int J Gynecol Cancer 19: 820-825, 2009.
18. Pecorelli S, Odicino F, Maisonneuve P, Creasman W, Shepherd J, Sideri M and Benedet J: Carcinoma of the ovary. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostat 3: 75-102, 1998.
19. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinumbased chemotherapy. J Clin Invest 94: 703-708, 1994.
20. Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I and Jakobsen A: Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 18: 702-710, 2008.
21. Stadlmann S, Dirnhofer S, Guth U, Thies S and Singer G: ERCC1 immunoexpression does not predict platinum-resistance in ovarian cancer. Gynecol Oncol 108: 252-253, 2008.
22. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, Antoniouk O, Goss G and Dimitroulakos J. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 124: 806-815, 2009.
23. Krivak TC, Darcy KM, Tian C, Bookman M, Gallion H, Ambrosone CB and Deloia JA: Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced-stage ovarian and primary peritoneal carcinoma; A Gynecologic Oncology Group Study. Gynecol Oncol 122: 121-126, 2011.
24. Kang S, Ju W, Kim JW, Park NH, Song YS, Kim SC, Park SY, Kang SB and Lee HP: Association between excision repair cross complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med 38: 320-324, 2006.
25. Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB and DeLoia JA: Relationship between ERCC1 polymorphisms, disease progression, and survival in the gynecologic oncology group phase III trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol 26: 3598-3606, 2008.
26. Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H and Katsaros D: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based chemotherapy. J Clin Oncol 25: 5172-5179, 2007.
27. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS and Kang SB: Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study. Gynecol Oncol 113: 264-269, 2009.
28. Marsh S, Paul J, King CR, Gifford G, Mcleod HL and Brown R: Pharmacogenetic assessment of toxicity and outcome after platinum taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25: 4528-4535, 2007.
29. Lin K, Ye D and Xie X: Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 18: 1007-1012, 2008.
30. Darcy KM, Tian C and Reed E: A Gynecologic Oncology Group study of platinum DNA adducts and excision repair crosscomplementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 67: 4474-4481, 2007.